Metabolic & Cardiometabolic
ezetimibe decreases liver fat
Part of: 💊 ezetimibe
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Ezetimibe modestly reduces hepatic fat and liver enzymes in NAFLD (meta-analysis; and ezetimibe+rosuvastatin beat rosuvastatin alone on MRI liver fat in ESSENTIAL) - a plausible incidental benefit of a statin+ezetimibe regimen. Surrogate-level only; no proof it reverses fibrosis or improves clinical liver outcomes.
The evidence (8)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Esim O et al 2025 · study_type: animal | animal | supports | low | High-fat-diet NAFLD rat model treated with free ezetimibe vs RBC-membrane-coated or uncoated PLGA nanoparticle-encapsulated ezetimibe; all ezetimibe-treated groups (including free-drug) showed significant reductions in hepatic lipid accumul |
| Patel 2016 · Therap Adv Gastroenterol | observational | supports | moderate | MRI-PDFF validation in NASH: quantifies hepatic-fat decline used as endpoint in ezetimibe trials |
| Cho Y, et al. (ESSENTIAL) 2022 · BMC Med | RCT | supports | low | [FT-verified] ESSENTIAL open-label per-protocol n=64 combo(eze+rosuva) MD 3.2%; ezetimibe added effect, no fibrosis; not blinded/placebo ↩ SUPERSEDED — pooled in the review above, counted once |
| Jiao B, et al. 2024 · Front Endocrinol | meta-analysis | contradicts | moderate | MA of RCTs: ezetimibe improved liver fat/aminotransferases (heterogeneous) |
| Loomba R, Sirlin CB, Ang B, et al. 2015 · Hepatology | RCT | contradicts | high | MOZART randomised placebo-controlled trial, liver fat by MRI-PDFF across nine colocalised segments plus MR elastography: 'Ezetimibe was NOT significantly better than placebo at reducing liver fat' (between-arm mean difference -1.3%, p=0.4). Within-arm fat fell in the ezetimibe group (15%->11.6%, p<0.016) but not placebo (18.5%->16.4%, p=0.15) - a within-arm change without a between-arm difference is not an effect. Well-powered imaging null on a directional claim -> contradicts per CONVENTIONS 5. |
| Xue F et al 2026 · study_type: RCT | RCT | contradicts | high | Phase 2a RCT, 210 Asian MASLD patients, 5 arms (HSK31679 3 doses, ezetimibe 10mg, placebo) for 12 weeks; primary endpoint relative change in MRI-PDFF liver fat content. Ezetimibe arm result not reported as significantly different from place |
| Xu Y et al 2026 · study_type: animal | animal | supports | moderate | Wild-type mice on NIAAA alcohol-feeding model +/- dietary cholesterol +/- ezetimibe (0.001% w/v); ezetimibe protected mice from cholesterol+alcohol-induced hepatic triglyceride accumulation and normalized liver cholesterol content, via enha |
| Masson 2025 · J Lipid Atheroscler | meta-analysis | mixed | moderate | [FT-verified] Masson2025 SR 18 studies/933: 5/8 ezetimibe RCTs no sig change; placebo-RCTs MOZART/LISTEN null; histo gains only non-RCT |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.